Company news
MediWound Ltd. news in 2022
MediWound Ltd.'s news releases, calls and decks from 2022, newest first.
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
December 28, 2022
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
December 22, 2022
MediWound Strengthens European Presence of NexoBrid®
December 19, 2022
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
December 18, 2022
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
December 12, 2022
MediWound Announces a 1-for-7 Reverse Share Split
December 4, 2022
MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update
November 14, 2022
MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs
November 8, 2022
MediWound to Report Third Quarter 2022 Financial Results
November 2, 2022
MediWound Announces Formation of Strategic Advisory Board
October 24, 2022
MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022
October 17, 2022
MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings
October 6, 2022
MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million
September 21, 2022
EMA Accepts MediWound’s Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns
September 19, 2022
MediWound’s NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress
September 11, 2022
MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates
August 8, 2022
MediWound Enhances Its Board and Executive Leadership Team
August 7, 2022
MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
August 2, 2022
MediWound Schedules Second Quarter 2022 Financial Results
July 31, 2022
MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
July 10, 2022
MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13
July 7, 2022
MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers
July 6, 2022
MediWound Names Mr. Tzvi Palash as Chief Operating Officer
June 29, 2022
MediWound Reports First Quarter 2022 Financial Results
May 16, 2022
MediWound Announces CEO Transition
May 16, 2022
MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
May 11, 2022
MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022
May 9, 2022
MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022
March 28, 2022
MediWound Announces Exercise of Over-Allotment Option
March 21, 2022
MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds
March 20, 2022
MediWound Reports Fourth Quarter and Full Year 2021 Financial Results
March 16, 2022
MediWound Announces Closing of Public Offering of Ordinary Shares
March 9, 2022
MediWound Announces Pricing of Public Offering of Ordinary Shares
March 2, 2022
MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares
March 1, 2022
MediWound Awarded a U.S. Department of Defense Research Grant for the Development of NexoBrid for the U.S. Army
February 16, 2022
MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol
February 9, 2022
MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
January 23, 2022
Calls in 2022
Decks in 2022
- Investor Presentation (July 2022)
Investor deck · 12 slides · Jul 12, 2022